A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer A Prospective, Open-label, Multi-center, Single-arm, Phase II Clinical Trial
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs Ensartinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Jan 2025 New trial record